New drugs targeting specific enzymes to treat Alzheimer's disease
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease
This study is testing new potential medications that could help improve memory and behavior in people with Alzheimer's by targeting specific proteins linked to the disease, and it's being done using mice to see how well these treatments work before they can be used in humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10922848 on NIH RePORTER |
What this research studies
This research focuses on developing new small-molecule inhibitors that target lysine methyltransferases G9a and GLP, which have been linked to the progression of Alzheimer's disease. The project aims to test these inhibitors in mouse models of Alzheimer's to assess their effectiveness in reversing cognitive and behavioral deficits. By optimizing these compounds, the researchers hope to create a viable drug candidate that can be further developed for clinical use in humans. Patients may benefit from a novel treatment option that addresses the underlying mechanisms of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that modifies the course of Alzheimer's disease.
How similar studies have performed: While targeting lysine methyltransferases is a relatively novel approach, preliminary studies have shown promise in related areas of Alzheimer's research.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Jin, Jian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Jin, Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.